GoodRx (NASDAQ:GDRX) Trading Up 5.8% – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) shot up 5.8% on Friday . The company traded as high as $4.54 and last traded at $4.53. 660,285 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 1,087,214 shares. The stock had previously closed at $4.28.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GDRX. Mizuho began coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. Citigroup lowered their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Morgan Stanley cut their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Barclays dropped their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, KeyCorp reduced their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, GoodRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.43.

GoodRx Stock Performance

The firm has a 50-day moving average price of $4.75 and a two-hundred day moving average price of $6.59. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market capitalization of $1.70 billion, a P/E ratio of -148.33, a P/E/G ratio of 3.43 and a beta of 1.27.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Fortem Financial Group LLC boosted its stake in GoodRx by 7.2% in the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after acquiring an additional 7,996 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of GoodRx by 358.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after purchasing an additional 18,997 shares in the last quarter. Franklin Resources Inc. purchased a new position in GoodRx during the 3rd quarter worth $5,675,000. Sanctuary Advisors LLC purchased a new position in GoodRx during the 3rd quarter worth $85,000. Finally, Barclays PLC increased its position in GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares in the last quarter. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.